Halozyme Therapeutics Balance Sheet
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Halozyme Therapeutics financial position
At the end of fiscal 2025, Halozyme Therapeutics reported total assets of $2.53 billion, up 22.4% from a year earlier against total liabilities of $2.48 billion. Shareholders' equity stood at $48.8 million, or 1.9% of assets. The company held $133.8 million in cash and equivalents against $2.14 billion of debt, a net debt position of $2.01 billion.
The current ratio (current assets divided by current liabilities) was 4.66, meaning short-term assets cover obligations due within a year. Debt-to-equity was 43.89.
Summary generated from market data by MetaCap's automated system. Methodology
Halozyme Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 133.82M | 115.85M | 118.37M | 234.19M | 118.72M | 147.70M | 120.18M | 57.94M | 168.74M | 66.76M |
| Short-Term Investments | — | — | — | 128.60M | 622.20M | 220.31M | 301.08M | 296.59M | 300.47M | 138.22M |
| Receivables | 426.27M | 288.20M | 233.25M | 186.97M | 90.97M | 97.73M | 59.44M | 30.00M | 22.13M | 15.68M |
| Inventory | 176.47M | 141.86M | 127.60M | 100.12M | 53.91M | 60.75M | 29.36M | 22.63M | 5.15M | 14.62M |
| Total Current Assets | 825.21M | 1.09B | 746.42M | 739.01M | 926.29M | 554.76M | 543.44M | 427.85M | 510.37M | 256.53M |
| Property, Plant & Equipment | 44.44M | 40.86M | 38.11M | 35.10M | 6.79M | 7.29M | 10.86M | 7.46M | 3.52M | 4.26M |
| Goodwill | 580.36M | 416.82M | 416.82M | 409.05M | 0 | — | — | — | — | — |
| Intangible Assets | 981.47M | 401.83M | 472.88M | 546.65M | 0 | — | — | — | — | — |
| Total Assets | 2.53B | 2.06B | 1.73B | 1.84B | 1.10B | 579.92M | 565.87M | 440.25M | 519.95M | 261.51M |
| Accounts Payable | 20.90M | 10.25M | 11.82M | 17.69M | 1.54M | 1.93M | 6.43M | 4.08M | 7.95M | 3.58M |
| Short-Term Debt | 0 | 0 | 0 | 13.33M | 89.42M | 397.23M | 19.54M | 91.51M | 77.21M | 17.39M |
| Total Current Liabilities | 177.09M | 139.10M | 112.49M | 130.79M | 117.15M | 421.38M | 85.64M | 149.36M | 131.33M | 54.59M |
| Long-Term Debt | 2.14B | 1.51B | 1.50B | 1.49B | 787.25M | 0 | 383.05M | 34.87M | 125.14M | 199.23M |
| Total Liabilities | 2.48B | 1.70B | 1.65B | 1.67B | 907.48M | 428.88M | 474.11M | 191.36M | 311.58M | 294.00M |
| Shareholders' Equity | 48.81M | 363.82M | 83.81M | 169.80M | 196.95M | 151.05M | 91.77M | 248.89M | 208.37M | -32.48M |
| Retained Earnings | 54.79M | 359.87M | 90.55M | 143.22M | -58.91M | -474.59M | -603.68M | -531.44M | -522.37M | -585.34M |
| Total Debt | 2.14B | 1.51B | 1.50B | 1.51B | 876.67M | 397.23M | 402.59M | 126.38M | 202.35M | 216.62M |
| Net Cash (Debt) | -2.01B | -1.39B | -1.38B | -1.14B | -135.75M | -29.21M | 18.68M | 228.15M | 266.86M | -11.64M |
| Shares Outstanding | 117.78M | 123.14M | 126.77M | 135.15M | 137.50M | 135.03M | 136.71M | 144.73M | 142.79M | 129.50M |
This table shows 10 annual periods of Halozyme Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow HALO's reporting calendar. What is a balance sheet?